Alan Colowick

Alan Colowick

Direktor/Vorstandsmitglied bei ACELYRIN, INC.

Vermögen: 16 883 $ am 30.04.2024

61 Jahre
Health Technology
Consumer Services
Finance

Profil

Alan B.
Colowick
founded Inventages II.
Dr. Colowick also currently works at Xylocor Therapeutics, Inc., as Director from 2018, ReCode Therapeutics, Inc., as Director from 2022, ACELYRIN, Inc., as Independent Director from 2021, Alumis, Inc., as Director from 2022, InCarda Therapeutics, Inc., as Director from 2018, Solve Therapeutics, Inc., as Director from 2021, Anumana, Inc., as Director from 2022, and Teon Therapeutics, Inc., as Director from 2017.
Dr. Colowick also formerly worked at Gloucester Pharmaceuticals, Inc., as Chief Executive Officer from 2008 to 2010, Principia Biopharma, Inc., as Chairman from 2017 to 2020, VelosBio, Inc., as Chairman from 2018 to 2020, Achaogen, Inc., as Independent Director from 2015 to 2017, Naryx Pharma, Inc., as Director, Personalis, Inc., as Independent Director from 2019 to 2023, Nora Therapeutics, Inc., as Director, Dimension Therapeutics, Inc., as Independent Non-Employee Class I Director from 2015 to 2017, Human Longevity, Inc., as Director from 2016 to 2019, Harpoon Therapeutics, Inc., as Independent Director from 2021 to 2023, AC Immune SA, as Independent Non-Executive Director from 2021 to 2023, Amgen, Inc., as Vice President-European Medical Affairs from 1999 to 2005, Celgene Corp., as Executive Vice President from 2010 to 2017, Geron Corp., as President-Oncology Division from 2006 to 2008, Threshold Pharmaceuticals, Inc., as Chief Medical Officer from 2005 to 2006, Celgene International SARL, as MD-Europe, Middle East & Africa Region, Sofinnova Investments, Inc., as Executive Partner & Private Equity, and Harvard University, as Principal in 1999.
Dr. Colowick received his undergraduate degree from The University of Colorado, graduate degree from Harvard T.H.
Chan School of Public Health, and doctorate degree from Stanford University School of Medicine.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
17.05.2023 13 506 ( 0,03% ) 16 883 $ 30.04.2024

Aktive Positionen von Alan Colowick

UnternehmenPositionBeginn
ACELYRIN, INC. Direktor/Vorstandsmitglied 01.11.2021
Direktor/Vorstandsmitglied 01.10.2018
Direktor/Vorstandsmitglied 01.02.2021
Direktor/Vorstandsmitglied 01.10.2017
Direktor/Vorstandsmitglied 01.01.2022
Direktor/Vorstandsmitglied 29.06.2022
Direktor/Vorstandsmitglied 01.10.2018
Direktor/Vorstandsmitglied 01.10.2022
Alle aktiven Positionen von Alan Colowick

Ehemalige bekannte Positionen von Alan Colowick

UnternehmenPositionEnde
HARPOON THERAPEUTICS, INC. Direktor/Vorstandsmitglied 22.06.2023
░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░ ░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Alan Colowick im Detail an

Ausbildung von Alan Colowick

The University of Colorado Undergraduate Degree
Stanford University School of Medicine Doctorate Degree
Harvard T.H. Chan School of Public Health Graduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Alan Colowick im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

30

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen6
AMGEN INC.

Health Technology

GERON CORPORATION

Health Technology

PERSONALIS, INC.

Health Services

HARPOON THERAPEUTICS, INC.

Health Technology

AC IMMUNE SA

Health Technology

ACELYRIN, INC.

Health Technology

Private Unternehmen20

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Technology Services

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Alan Colowick